{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oxybutynin+IR",
    "query": {
      "intervention": "oxybutynin IR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T21:35:38.111Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03187795",
      "title": "Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Urinary Bladder, Neurogenic"
      ],
      "interventions": [
        {
          "name": "Oxybutynin Chloride IR",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 62,
      "start_date": "2019-04-03",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-11T21:35:38.111Z",
      "location_count": 1,
      "location_summary": "West Orange, New Jersey",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03187795"
    },
    {
      "nct_id": "NCT01178827",
      "title": "Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "trospium chloride",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin IR",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin IR placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-08",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-02-26",
      "last_synced_at": "2026-09-11T21:35:38.111Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178827"
    },
    {
      "nct_id": "NCT02386072",
      "title": "A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Bladder Overactive",
        "Overactive Bladder",
        "Urinary Bladder Diseases",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "mirabegron",
          "type": "DRUG"
        },
        {
          "name": "antimuscarinic medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Scientific & Medical Affairs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1524,
      "start_date": "2015-01-05",
      "completion_date": "2017-08-04",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-09-11T21:35:38.111Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02386072"
    }
  ]
}